Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488318 · ClinicalTrials.gov registry record · Phase 2
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
A Phase 2 study, sponsored by Julie E. Bauman, MD, MPH.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT01488318: Clinical Trial Phase 2 study, sponsored by Julie E. Bauman, MD, MPH.
NCT01488318 is a Phase 2 study that was terminated before completion, run by Julie E. Bauman, MD, MPH. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01488318, a Phase 2 study, was terminated before completion, sponsored by Julie E. Bauman, MD, MPH.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached schema). The primary endpoint 12-week PFS.
Primary Outcome
Number of patients experiencing a Complete Response (CR) + Partial Response (PR) to study treatment / Total number of evaluable patients, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Interventions
- DRUG Cetuximab
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Why NCT01488318 stopped before completion
NCT01488318 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT01488318 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01488318 about?
NCT01488318 is a clinical study titled "Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma". This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached schema). The primary endpoint 12-week PFS.
What is the current status of trial NCT01488318?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2011-09. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01488318?
The interventions under investigation include: Cetuximab (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT01488318?
This trial is sponsored by Julie E. Bauman, MD, MPH, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01488318's enrollment target sits among peer trials
21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia